Tempest Therapeutics receives ODD from EMA for amezalpat

Tempest Therapeutics (TPST) announced that the European Medicines Agency, EMA, has granted Orphan Drug Designation, ODD, to amezalpat, TPST-1120, an oral, small molecule, selective PPARalpha antagonist for the treatment of patients with hepatocellular carcinoma. “We’re incredibly pleased to receive Orphan Drug Designation from the EMA, building on the momentum of regulatory support we’ve already received from the FDA,” said Stephen Brady, president and chief executive officer of Tempest. “These designations reflect the significant unmet need in liver cancer and reinforce our belief in the potential of amezalpat to make a meaningful difference for patients and families affected by this devastating disease.”